John P. Rearick, Ph.D.

Patent Prosecution and Counseling

• Celgene in a global portfolio covering covalent small molecule inhibitors in a crowded patent landscape, including claims to protein-inhibitor conjugates agnostic to inhibitor structure.
• Forma Therapeutics in executing a strategic series of patents filings to extend exclusivity period for phase II drug candidate.
• A large pharmaceutical company in procuring the first Orange Book listable patent for an already approved drug.
• A small pharmaceutical company on patent filing strategy for a small molecule series showing activity against multiple targets of clinical interest.
• Saudi Aramco in a European opposition and appeal involving defending a key patent on innovative polymers and challenging third party patent rights in foreign jurisdictions.
• Saudi Aramco in a patent invalidation trial and appeal in South Korea.
• A large pharmaceutical company in conducting extensive pre-ANDA litigation analysis of a newly approved drug.
• Underwriters and private companies in IP due diligence analyses and opinions in the context of initial public offerings.
• Forma Therapeutics as lead IP counsel in its US$278 million initial public offering.

Patent Trial and Appeal Board

• Valo Early Discovery, Inc. (f/k/a Integral Early Discovery, Inc.) in an appeal of a PTAB post-grant review decision involving a patent protecting novel inhibitors of ubiquitin-specific protease 7 (USP7).
• Progenics Pharmaceuticals, Inc. in a PGR proceeding challenging a patent directed to compounds for preparing 18F-radiolabeled Prostate-Specific Membrane Antigen (PSMA)-targeting conjugates.
• Forma Therapeutics, Inc. in a PGR proceeding defending a patent protecting novel inhibitors of ubiquitin-specific protease 7 (USP7).
• Saudi Arabian Oil Co. in an IPR proceeding challenging a patent directed to polycarbonates.

Includes matters handled at Dechert or prior to joining the firm.